Sofina Ventures Trims Honasa Stake With ₹177 Cr Bulk Deal at ₹424/Share
Belgian PE Sofina Ventures offloaded a 1.28% stake (41.78 lakh shares) in Mamaearth parent Honasa Consumer for ₹177.2 Cr at ₹424.07 apiece. The exit comes as Honasa pushes its 3.0 strategy, closes a ₹135 Cr Fluence Pharma deal for 58%, and targets ₹5,500 Cr revenue by FY31 with 15% EBITDA, even as the stock is down 42% YTD.
What happened
Sofina Ventures sold a 1.28% stake in Honasa Consumer via a ₹177 Cr bulk deal at ₹424/share, trimming its position further as the Mamaearth parent pushes its
Key facts
- ₹177.2 Cr
- 41.78 Lakh shares
- ₹424.07
- 1.28% stake
- ₹135 Cr Fluence deal
- 58% stake
- ₹5,500 Cr FY31 target
- 15% EBITDA
- 42% YTD
Why this matters
The ₹135 Cr Fluence Pharma deal for 58% shows Honasa is pivoting to inorganic growth—scout adjacent BPC niches where bolt-ons can defend the FY31 thesis.
What to watch
- Block deal screens for other PE holders (Stellaris, Fireside, Sofina residual ~remaining stake)
- Q2FY26 results - volume growth and Mamaearth brand revenue trajectory
- Fluence Pharma integration milestones and revenue contribution disclosure
- Direct distribution rollout metrics under 3.0 strategy
- Promoter pledge/stake changes by Varun and Ghazal Alagh
- Honasa IR likely to fast-track investor roadshows highlighting Fluence synergies and 3.0 distribution reset
- Expect management commentary defending FY31 guidance on next earnings call
- Possible buyback or promoter signaling to stem sentiment damage
- Competitive response from Plum, Minimalist (Hul), Wow Skin Science to capture share during Mamaearth's distribution transition